Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab

Table 1 Patient’s characteristics and their correlations with STAT3 polymorphism genotypes

Clinical parameters	No.	Genotype		p	Clinical parameters	No.	Genotype		p
		CC + GG	CG				CC + GG	CG
Gender					IPI score
Male	82	50	32	0.042	0-2	116	61	55	0.867
Female	84	38	46		3-5	50	27	23
Age					Bulky mass
≤60	106	59	47	0.364	≥10 cm	33	19	14	0.557
>60	60	29	31		<10 cm	133	69	64
B symptoms					Localized
Positive	63	31	32	0.442	Yes	27	17	10	0.258
Negative	103	57	46		No	139	71	68
LDH					Extra Nodal Site
Positive	78	39	39	0.464	≤1	123	64	59	0.669
Negative	88	49	39		>1	43	24	19
β-2 MG					Incidence Site
Positive	51	23	28	0.091	Lymph node	95	46	49	0.170
Negative	106	63	43		Extra lymph	71	42	29
ESR					Ki-67
Positive	77	36	41	0.132	≤75	66	32	34	0.329
Negative	80	47	33		>75	85	48	37
Stage					Subtype
I-II	78	42	36	0.839	GCB	29	18	11	0.229
III-IV	88	46	42		Non-GCB	113	56	57

ISSN: 1475-2867